NFE2L2 and hepatocellular carcinoma: Several studies of HCC cells have shown that inhibition of NFE2L2 expression can increase the anticancer activity of the chemicals erastin and sorafenib, with inhibition of NFE2L2 inducing ferroptosis and killing HCC cells (64).